Copyright Reports & Markets. All rights reserved.

Digital Diabetes Global Market - Forecast to 2026

Request for Sample of this report
Buy now

1 EXECUTIVE SUMMARY 25

    2 INTRODUCTION 29

    • 2.1 KEY TAKEAWAYS 29
    • 2.2 SCOPE OF THE REPORT 30
    • 2.3 REPORT DESCRIPTION 30
    • 2.4 MARKETS COVERED 32
    • 2.5 STAKEHOLDERS 33
    • 2.6 RESEARCH METHODOLOGY 33
      • 2.6.1 MARKET SIZE ESTIMATION 35
      • 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 37
      • 2.6.3 SECONDARY SOURCES 38
      • 2.6.4 PRIMARY SOURCES 39
      • 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 39
      • 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 40
      • 2.6.7 ASSUMPTIONS 40

    3 MARKET ANALYSIS 42

    • 3.1 INTRODUCTION 42
    • 3.2 MARKET SEGMENTATION 43
    • 3.3 FACTORS INFLUENCING MARKET 44
      • 3.3.1 DRIVERS AND OPPORTUNITIES 45
        • 3.3.1.1 The global rise in the prevalence and incidence of diabetes 45
        • 3.3.1.2 Technological advancements in digital diabetes devices 46
        • 3.3.1.3 Growing diffusion of smart devices and digital platforms 46
        • 3.3.1.4 Increasing r & d investments 47
      • 3.3.2 RESTRAINS AND THREATS 48
        • 3.3.2.1 High cost associated with the products 48
        • 3.3.2.2 Product recalls 49
        • 3.3.2.3 Inadequate reimbursement 50
        • 3.3.2.4 Strict regulation of glucose monitoring devices by regulatory organizations

      like the fda and others 51

      • 3.3.2.5 Privacy concern and safety issues in digital diabetes 53
  • 3.4 MARKET SHARE ANALYSIS 54
    • 3.4.1 DIGITAL DIABETES GLOBAL MARKET SHARE ANALYSIS 54
    • 3.4.2 CONTINUOUS GLUCOSE MONITOR (CGM) MARKET SHARE ANALYSIS 58
    • 3.4.3 SMART INSULIN PUMP MARKET SHARE ANALYSIS 60
  • 3.5 REGULATORY AFFAIRS 63
    • 3.5.1 U.S. 63
    • 3.5.2 EUROPE 67
    • 3.5.3 CHINA 68
    • 3.5.4 INDIA 70
    • 3.5.5 JAPAN 72
  • 3.6 TECHNOLOGICAL ADVANCEMENTS 73
    • 3.6.1 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING 73
  • 3.7 CLINICAL TRIALS 74
  • 3.8 FUNDING SCENARIO 77
  • 3.9 DIGITAL DIABETES – DEALS, APPROVALS AND NEW PRODUCT LAUNCH 80
  • 3.10 APPROVAL 95
  • 3.11 FDA AND CE APPROVED DIABETES MANAGEMENT APPS 96
  • 3.12 PRODUCT LAUNCH 98
  • 3.13 REVENUE MODEL 99
    • 3.13.1 INTRODUCTION 99
    • 3.13.2 FREEMIUM MODEL 100
    • 3.13.3 THIRD PARTY PAYMENT MODEL 100
    • 3.13.4 DIFFERENT REVENUE STREAMS MODEL 100
    • 3.13.5 LOWER PRICING MODEL 101
    • 3.13.6 NEW PAYMENT MODEL OR NEW PRICING MODEL 101
  • 3.14 PORTER’S FIVE FORCE ANALYSIS 101
    • 3.14.1 THREAT OF NEW ENTRANTS 102
    • 3.14.2 THREAT OF SUBSTITUTES 103
    • 3.14.3 BARGAINING POWER OF SUPPLIERS 104
    • 3.14.4 BARGAINING POWER OF BUYERS 104
    • 3.14.5 RIVALRY AMONG EXISTING COMPETITORS 105
  • 3.15 PATENT ANALYSIS 106
  • 3.16 UNITS SOLD 107
    • 3.16.1 GLUCOSE TESTING STRIPS UNITS SOLD 107
    • 3.16.2 CGM SENSORS UNITS SOLD 109
    • 3.16.3 SMART INSULIN PUMP UNITS SOLD 111
    • 3.16.4 SMART INSULIN PEN UNITS SOLD 113
  • 3.17 MARKET PENETRATION 115

    • 4 DIGITAL DIABETES GLOBAL MARKET, BY PRODUCTS 118

    • 4.1 INTRODUCTION 118
    • 4.2 DEVICES 122
      • 4.2.1 SMART BLOOD GLUCOSE MONITORING(SBGM) 126
        • 4.2.1.1 Smart blood glucose meter 131
        • 4.2.1.2 Blood glucose testing strips 135
        • 4.2.1.3 Lancets 137
        • 4.2.1.4 Others 141
      • 4.2.2 CONTINUOUS GLUCOSE MONITORING (CGM) 144
        • 4.2.2.1 Glucose sensors 151
        • 4.2.2.2 Transmitter and receivers 153
      • 4.2.3 SMART INSULIN PUMP 155
        • 4.2.3.1 Traditional insulin pump 161
        • 4.2.3.2 Patch insulin pump 163
      • 4.2.4 SMART INSULIN PEN 167
    • 4.3 APPS AND SOFTWARE 170

    5 DIGITAL DIABETES GLOBAL MARKET, BY END-USERS 175

    • 5.1 INTRODUCTION 175
    • 5.2 HOME CARE 178
    • 5.3 HOSPITALS AND PRIVATE CLINICS 181
    • 5.4 OTHERS 186

    6 REGIONAL ANALYSIS 189

    • 6.1 INTRODUCTION 189
    • 6.2 NORTH AMERICA 193
      • 6.2.1 U.S. 210
      • 6.2.2 REST OF N.A. 216
    • 6.3 EUROPE 220
      • 6.3.1 GERMANY 237
      • 6.3.2 FRANCE 242
      • 6.3.3 ITALY 246
      • 6.3.4 REST OF EUROPE 250
    • 6.4 ASIA - PACIFIC 254
      • 6.4.1 JAPAN 271
      • 6.4.2 CHINA 274
      • 6.4.3 INDIA 279
      • 6.4.4 REST OF APAC 283
    • 6.5 REST OF THE WORLD 288
      • 6.5.1 BRAZIL 304
      • 6.5.2 REST OF LATIN AMERICA 308
      • 6.5.3 MIDDLE EAST & OTHERS 312

    7 COMPETITIVE LANDSCAPE 316

    • 7.1 INTRODUCTION 316
    • 7.2 COLLABORATION, AGREEMENTS AND PARTNERSHIPS 317
    • 7.3 APPROVALS 321
    • 7.4 NEW PRODUCT LAUNCH 326
    • 7.5 ACQUISITION 327
    • 7.6 EXPANSION 329
    • 7.7 OTHER DEVELOPMENTS 329

    8 MAJOR PLAYER PROFILES 332

    • 8.1 ABBOTT LABORATORIES 332
      • 8.1.1 OVERVIEW 332
      • 8.1.2 FINANCIALS 333
      • 8.1.3 PRODUCT PORTFOLIO 336
      • 8.1.4 KEY DEVELOPMENTS 337
      • 8.1.5 BUSINESS STRATEGY 338
      • 8.1.6 SWOT ANALYSIS 339
    • 8.2 DEXCOM, INC 340
      • 8.2.1 OVERVIEW 340
      • 8.2.2 FINANCIALS 341
      • 8.2.3 PRODUCT PORTFOLIO 344
      • 8.2.4 KEY DEVELOPMENTS 345
      • 8.2.5 BUSINESS STRATEGY 346
      • 8.2.6 SWOT ANALYSIS 347
    • 8.3 F. HOFFMANN-LA ROCHE AG. 348
      • 8.3.1 OVERVIEW 348
      • 8.3.2 FINANCIALS 349
      • 8.3.3 PRODUCT PORTFOLIO 354
      • 8.3.4 KEY DEVELOPMENTS 355
      • 8.3.5 BUSINESS STRATEGY 355
      • 8.3.6 SWOT ANALYSIS 356
    • 8.4 INSULET CORPORATION 357
      • 8.4.1 OVERVIEW 357
      • 8.4.2 FINANCIALS 358
      • 8.4.3 PRODUCT PORTFOLIO 360
      • 8.4.4 KEY DEVELOPMENTS 361
      • 8.4.5 BUSINESS STRATEGY 363
      • 8.4.6 SWOT ANALYSIS 364
    • 8.5 I-SENS, INC. 365
      • 8.5.1 OVERVIEW 365
      • 8.5.2 FINANCIALS 365
      • 8.5.3 KEY DEVELOPMENTS 365
      • 8.5.4 PRODUCT PORTFOLIO 366
      • 8.5.5 BUSINESS STRATEGY 366
      • 8.5.6 SWOT ANALYSIS 367
    • 8.6 LIVONGO HEALTH, INC. 368
      • 8.6.1 OVERVIEW 368
      • 8.6.2 FINANCIALS 369
      • 8.6.3 KEY DEVELOPMENTS 370
      • 8.6.4 PRODUCT PORTFOLIO 371
      • 8.6.5 BUSINESS STRATEGY 371
      • 8.6.6 SWOT ANALYSIS 372
    • 8.7 MEDTRONIC, PLC 373
      • 8.7.1 OVERVIEW 373
      • 8.7.2 FINANCIALS 374
      • 8.7.3 PRODUCT PORTFOLIO 377
      • 8.7.4 KEY DEVELOPMENTS 378
      • 8.7.5 BUSINESS STRATEGY 379
      • 8.7.6 SWOT ANALYSIS 380
    • 8.8 SENSEONICS HOLDINGS, INC. 381
      • 8.8.1 OVERVIEW 381
      • 8.8.2 FINANCIALS 382
      • 8.8.3 PRODUCT PORTFOLIO 384
      • 8.8.4 KEY DEVELOPMENTS 384
      • 8.8.5 BUSINESS STRATEGY 386
      • 8.8.6 SWOT ANALYSIS 387
    • 8.9 TANDEM DIABETES CARE INC. 388
      • 8.9.1 OVERVIEW 388
      • 8.9.2 FINANCIALS 389
      • 8.9.3 PRODUCT PORTFOLIO 392
      • 8.9.4 KEY DEVELOPMENTS 392
      • 8.9.5 BUSINESS STRATEGY 395
      • 8.9.6 SWOT ANALYSIS 396
    • 8.10 YPSOMED HOLDING AG. 397
      • 8.10.1 OVERVIEW 397
      • 8.10.2 FINANCIALS 398
      • 8.10.3 PRODUCT PORTFOLIO 400
      • 8.10.4 KEY DEVELOPMENTS 401
      • 8.10.5 BUSINESS STRATEGY 402

    Digital diabetes includes products utilizing advanced technologies for monitoring, managing and tools that help in deciding optimum therapy options in the patients suffering from diabetes. These devices help in monitoring of blood sugar levels, calorie counting, and in insulin dose calculation, reduce complications to improve the quality of life of diabetics. According to IQ4I analysis, digital diabetes global market expected to reach $16,329.6 million by 2026 growing at a high single digit CAGR from 2019 to 2026.
    The digital diabetes global market is segmented based on products, end-users and geography. The product market is further segmented into devices and apps and software. As estimated by IQ4I Research, the devices global market is expected to grow at a mid single CAGR from 2019 to 2026. The apps and software global market is expected to grow at a strong double digit CAGR from 2019 to 2026 due to growing adoption of digital solutions such as cloud based software, technology advancements such as incorporating artificial intelligence to manage the diabetes are driving the market. However, privacy and data safety issues, stringent regulatory approvals, lack of reimbursement are restraining the market growth.
    The digital diabetes devices global market by product type is segmented into SBGM, CGM, Smart Insulin Pumps, and Smart Insulin Pens. CGM accounted the largest market revenue in 2019 and is expected grow at a double digit CAGR from 2019 to 2026 due to increasing number of regulatory approvals for CGM systems; technological advancements in devices and other pipeline devices. SBGM products are further segmented into Smart Blood glucose meter, Blood glucose testing-strips, Lancets and control solution. Blood glucose testing-strips accounted largest revenue in 2019. CGM products are further segmented into glucose sensors and transmitter and receiver. Glucose sensor commanded the largest revenue in 2019 and is expected grow at a double digit CAGR due to increasing adoption of CGM systems, development of advanced CGM systems, and favourable government policies in developed countries promoting adoption of CGM systems. The smart insulin pump products are further segmented into traditional insulin pump and patch pump. Traditional insulin pump held largest revenue in 2019 and expected to grow at a mid single digit CAGR from 2019 to 2026 and Patch pump are expected to grow at a double digit CAGR from 2019 to 2026.
    The Digital diabetes end-user market is segmented into homecare, hospitals & private clinics and others which include ambulatory setting, academic and research institutes. Homecare accounted for largest revenue in 2019. The largest revenue of this segment can be mainly attributed to technological advancements and a shift toward home care and self-management of diabetes, increase in prevalence of diabetes disease, the improvement and acceptance of home care devices has increased. In addition, growing focus of companies to increase awareness about diabetes and glucose management devices & apps are further driving the adoption in home care settings. Homecare is the fastest growing segment with projected high single digit CAGR from 2019 to 2026 due to increase of self management of diabetes using apps and software at home itself.
    Geographical wise, North America region commanded the largest revenue in 2019 and expected to grow at a mid single digit CAGR from 2019 to 2026. Some of the driving factors are increased awareness of the benefits of using continuous glucose monitoring systems, growing diffusion of smart devices, increasing prevalence and incidences of diabetes due to obesity and better accessibility to technologies compared to other regions and presence of well-established distribution channels of the major players in this region. However, Asia-Pacific region is expected to grow at a double digit strong CAGR from 2019 to 2026 due to large pool of patients with diabetes, increasing patient awareness about diabetes, and increasing affordability of advanced treatment due to increasing prosperity.
    The digital diabetes global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players in the digital diabetes global market are Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Insulet Corporation (U.S.), i-Sens, Inc (South Korea), Livongo Health, Inc. (U.S.), Medtronic PLC (Ireland), F.Hoffmann-LA Roche AG (Switzerland), Senseonics Holdings Inc. (U.S.), Tandem Diabetes Care (U.S.), and Ypsomed Holding AG (Switzerland).
    The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
    • North America (U.S. and Rest of N.A.)
    • Europe (Germany, France, Italy and Rest of E.U.)
    • Asia-Pacific (Japan, China, India and Rest of APAC)
    • Rest of the World (RoW) (Brazil, Rest of Latin-America and Middle East & Others)
    Buy now